AAPL vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Apple Inc. · Technology
$260.88
+135.9% upside to fair value
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$238.46
-11.8% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
AAPL has more upside to fair value
(+135.9%).
JNJ trades at a lower forward P/E
(20.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
JNJ |
| Current Price |
$260.88 |
$238.46 |
| Fair Value Estimate |
$615.48 |
$210.28 |
| Upside to Fair Value |
+135.9%
|
-11.8%
|
| Market Cap |
$3,834.4B |
$574.7B |
| Forward P/E |
32.6x
|
20.2x
|
| EV / EBITDA |
25.4x
|
13.3x
|
| Price / Sales |
8.8x
|
6.2x
|
| Price / FCF |
31.1x
|
29.4x
|
| Revenue Growth YoY |
+40.3%
|
+6.1%
|
| Gross Margin |
47.3%
|
72.8%
|
| Operating Margin |
32.4%
|
27.2%
|
| Return on Equity |
159.9%
|
32.87%
|
| Dividend Yield |
0% |
2.18% |
| FCF Yield |
3.21%
|
3.4%
|
| Analyst Consensus |
Strong Buy
|
Moderate Buy
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services with a strong brand and durable competitive advantages. The business quality is high, demonstrated by exceptional profitability metrics including a 159.9% return on equity, 40.3% revenue growth year-over-year, and 53.3% earnings growth year-over-year. Despite these fundamentals, the stock is cu…
Johnson & Johnson is a high-quality healthcare conglomerate focused exclusively on Innovative Medicine and MedTech following the Kenvue spin-off. The company delivered $94.2B in FY2025 revenue with 6% operational growth, generated $19.7B in free cash flow, and guided for $99.5-100.5B in 2026 operational sales (above consensus). However, at $238 the stock trades at a P/S of 6.15x, well above the 5…
Accumulation Zones
| Metric |
AAPL |
JNJ |
| Zone Low |
$461.61 |
$157.71 |
| Zone High |
$523.16 |
$178.74 |
| In Buy Zone? |
Yes
|
No
|